flow trial semaglutide kidney outcomes 2024 soul oral cardiovascular results 🔴Cardiovascular outcomes with semaglutide by severity of The FLOW trial for semaglutide
Description
doi: 10.1111/j.1365-2982.2009.01317.x
Z.EdwardsR.et al (2022)
Fatime Cody Stanford, an obesity medicine physician at Mass General Brigham and associate professor at Harvard Medical School, warns that compounded versions of the drugs are not the same and they are not tested
Dulaglutide and tirzepatide yielded even less benefit (2.3% loss and 2.3% gain, respectively), suggesting that concurrent endocrine therapy may attenuate the weight loss efficacy of GLP-1 RAs in this population
There are no drug interactions or systemic concerns
Ali recommended
